Fertility in the Adolescent and Young Adult Patient with Cancer

  • Nivedita ReddyEmail author
  • Caroline L. Furness
  • Melanie C. Davies


In recent years significant progress in cancer therapy has led to vastly improved survival rates in the adolescent and young adult diagnosed with cancer. Many patients receive treatment that results in the loss or compromise of future fertility. This has led to a greater focus on reproduction as an important aspect of survivorship. The simultaneous advances in assisted reproductive technology has meant that young people have a better opportunity for future fertility. Though national and international guidance recommend discussion and provision of fertility preservation where practicable there is considerable variation in clinical practice. Oncofertility centres set up in association with larger cancer centres has enabled a rapid access to specialist fertility services, and long term care of gonadal dysfunction in young cancer patients. It is hoped that development of oncofertility networks in the future will enable these resources to be accessed by all cancer centres and many more young people to avail of these services. In this chapter we provide a comprehensive understanding of the effect of cancer therapy on fertility and options of fertility preservation.


Fertility preservation Adolescent Young adult Cancer Chemotherapy Radiotherapy Oncofertility Reproduction Pregnancy outcome Uptake of frozen sperm Oocyte cryopreservation Safety in fertility preservation Genital GVHD Menstrual suppression during chemotherapy 


  1. 1.
    O’Hara C, Moran A, Whelan JS, Hough RE, Stiller CA, Stevens MC, Stark DP, Feltbower RG, McCabe MG. Trends in survival for teenagers and young adults with cancer in the UK 1992-2006. Eur J Cancer. 2015;51(14):2039–48.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    CRUK, R. o. t. i. c. t. Achieving world class cancer outcomes—a strategy for england 2015–2020. 2015.
  3. 3.
    NHSEngland. NHS standard contract for cancer: teenagers and young adults. 2013.
  4. 4.
    NICE, c. g.-. (2013). “Fertility: assessment and treatment for people with fertility problems.” NICE Clinical Guideline 156
  5. 5.
    Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Salsman JM, Yanez B, Smith KN, Beaumont JL, Snyder MA, Barnes K, Clayman ML. Documentation of fertility preservation discussions for young adults with cancer: examining compliance with treatment guidelines. J Natl Compr Canc Netw. 2016;14(3):301–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Adams E, Hill E, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists’ current knowledge, practice and attitudes. Br J Cancer. 2013;108(8):1602–15.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ben-Aharon I, Abir R, Perl G, Stein J, Gilad G, Toledano H, Elitzur S, Avrahami G, Ben-Haroush A, Oron G, Freud E, Kravarusic D, Ben-Arush M, Herzel G, Yaniv I, Stemmer SM, Fisch B, Ash S. Optimizing the process of fertility preservation in pediatric female cancer patients - a multidisciplinary program. BMC Cancer. 2016;16:620.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Louwe LA, Stiggelbout AM, Overbeek A, Hilders CG, van den Berg MH, Wendel E, van Dulmen-den Broeder E, Ter Kuile MM. Factors associated with frequency of discussion of or referral for counselling about fertility issues in female cancer patients. Eur J Cancer Care (Engl). 2016.Google Scholar
  10. 10.
    Nielsen CT, Skakkebaek NE, Richardson DW, Darling JA, Hunter WM, Jorgensen M, Nielsen A, Ingerslev O, Keiding N, Muller J. Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. J Clin Endocrinol Metab. 1986;62(3):532–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Schaefer F, Marr J, Seidel C, Tilgen W, Scharer K. Assessment of gonadal maturation by evaluation of spermaturia. Arch Dis Child. 1990;65(11):1205–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Keene DJ, Sajjad Y, Makin G, Cervellione RM. Sperm banking in the United Kingdom is feasible in patients 13 years or older with cancer. J Urol. 2012;188(2):594–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Bahadur G, Ling KL, Hart R, Ralph D, Wafa R, Ashraf A, Jaman N, Mahmud S, Oyede AW. Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod. 2002;17(12):3157–61.CrossRefPubMedGoogle Scholar
  14. 14.
    Hagenas I, Jorgensen N, Rechnitzer C, Sommer P, Holm M, Schmiegelow K, Daugaard G, Jacobsen N, Juul A. Clinical and biochemical correlates of successful semen collection for cryopreservation from 12-18-year-old patients: a single-center study of 86 adolescents. Hum Reprod. 2010;25(8):2031–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Kamischke A, Jurgens H, Hertle L, Berdel WE, Nieschlag E. Cryopreservation of sperm from adolescents and adults with malignancies. J Androl. 2004;25(4):586–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res. 1974;59(3):665–78.CrossRefPubMedGoogle Scholar
  17. 17.
    Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol. 1999;17(3):941–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Agarwal A, Allamaneni SS. Disruption of spermatogenesis by the cancer disease process. J Natl Cancer Inst Monogr. 2005;34:9–12.CrossRefGoogle Scholar
  19. 19.
    Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen FJ, Tesch H, Bredenfeld H, Koch P, Nisters-Backes H, Wolf J, Engert A, Diehl V. Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment. Ann Oncol. 2001;12(9):1307–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Williams DH t, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol. 2009;181(2):736–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Ferreira U, Netto Junior NR, Esteves SC, Rivero MA, Schirren C. Comparative study of the fertility potential of men with only one testis. Scand J Urol Nephrol. 1991;25(4):255–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Apperley JF, Reddy N. Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev. 1995;9(2):93–116.CrossRefPubMedGoogle Scholar
  23. 23.
    Colpi GM, Contalbi GF, Nerva F, Sagone P, Piediferro G. Testicular function following chemo-radiotherapy. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl 1):S2–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, Lombardo F, Lenzi A, Gandini L. Spermatogenesis in Hodgkin’s lymphoma patients: spermatogenesis in Hodgkin’s lymphoma patientsa retrospective study of semen quality before and after different chemotherapy regimens. Hum Reprod. 2016;31(2):263–72.PubMedGoogle Scholar
  25. 25.
    Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, Engert A. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin study group (GHSG). Blood. 2008;111(1):71–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlputz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wollff M, van der Ven K, Huehr M, Fuchs M, Diehl V, Engert A, Borchmann P. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Choudhury RC, Jagdale MB, Misra S. Cytogenetic toxicity of cisplatin in bone marrow cells of Swiss mice. J Chemother. 2000a;12(2):173–82.CrossRefPubMedGoogle Scholar
  28. 28.
    Choudhury RC, Jagdale MB, Misra S. Potential transmission of the cytogenetic effects of cisplatin in the male germline cells of Swiss mice. J Chemother. 2000b;12(4):352–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. NOVP chemotherapy for Hodgkin’s disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Cancer Res. 2003;63(1):44–51.PubMedGoogle Scholar
  30. 30.
    Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet. 1997;16(1):74–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril. 2013;100(5):1180–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Martin RH, Ernst S, Rademaker A, Barclay L, Ko E, Summers N. Analysis of sperm chromosome complements before, during, and after chemotherapy. Cancer Genet Cytogenet. 1999;108(2):133–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Rives N, Walschaerts M, Setif V, Hennebicq S, Saias J, Brugnon F, Auger J, Berthaut I, Szerman E, Daudin M, Bujan L. Sperm aneuploidy after testicular cancer treatment: data from a prospective multicentre study performed within the French Centre d’Etude et de conservation des Oeufs et du Sperme network. Fertil Steril. 2017;107(3):580–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Brandriff BF, Meistrich ML, Gordon LA, Carrano AV, Liang JC. Chromosomal damage in sperm of patients surviving Hodgkin’s disease following MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy with and without radiotherapy. Hum Genet. 1994;93(3):295–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Martinez G, Walschaerts M, Le Mitouard M, Borye R, Thomas C, Auger J, Berthaut I, Brugnon F, Daudin M, Moinard N, Ravel C, Saias J, Szerman E, Rives N, Hennebicq S, Bujan L. Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: a prospective study by the French CECOS network. Fertil Steril. 2017;107(2):341–350.e5. Epub 2016 Oct 31CrossRefPubMedGoogle Scholar
  36. 36.
    Tempest HG, Ko E, Chan P, Robaire B, Rademaker A, Martin RH. Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin’s lymphoma patients. Hum Reprod. 2008;23(2):251–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Hansen PV, Trykker H, Svennekjaer IL, Hvolby J. Long term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. Radiother Oncol. 1990;18(2):117–25.CrossRefPubMedGoogle Scholar
  38. 38.
    Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F, Bacigalupo A. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002;30(7):447–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Centola GM, Keller JW, Henzler M, Rubin P. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. J Androl. 1994;15(6):608–13.PubMedGoogle Scholar
  40. 40.
    Kinsella TJ, Trivette G, Rowland J, Sorace R, Miller R, Fraass B, Steinberg SM, Glatstein E, Sherins RJ. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin’s disease. J Clin Oncol. 1989;7(6):718–24.CrossRefPubMedGoogle Scholar
  41. 41.
    Sandeman TF. The effects of x irradiation on male human fertility. Br J Radiol. 1966;39(468):901–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R, Appelbaum FR. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87(7):3045–52.PubMedGoogle Scholar
  43. 43.
    Petersen PM, Giwercman A, Daugaard G, Rørth M, Petersen JH, Skakkeaek NE, Hansen SW, von der Maase H. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol. 2002;20(6):1537–43.Google Scholar
  44. 44.
    Brauner R, et al. Leydig cell function in children after direct testicular irradiation for acute lymphoblastc leukaemia. N Engl J Med. 1983;309:25–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Sklar CA, Robison LL, Nesbit ME, Sather HN, Meadows AT, Ortega JA, Kim TH, Hammond GD. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990;8(12):1981–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang JH, Muller CH, Lin K. Optimizing fertility preservation for pre- and postpubertal males with cancer. Semin Reprod Med. 2013;31(4):274–85.CrossRefPubMedGoogle Scholar
  47. 47.
    Bunge RG, Sherman JK. Fertilizing capacity of frozen human spermatozoa. Nature. 1953;172(4382):767–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Ragni G, Somigliana E, Restelli L, Salvi R, Arnoldi M, Paffoni A. Sperm banking and rate of assisted conception treatment indights from a 15 year cryopreservation programme for male cancer patients. Cancer. 2003;97:1624–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Roque M, Sampaio M, Salles PG, Geber S. Onco-testicular sperm extraction: Birth of a healthy baby after fertility preservation in synchronous bilateral testicular cancer and azoospermia. Andrologia. 2015;47(4):482–5.CrossRefPubMedGoogle Scholar
  50. 50.
    Onofre J, Baert Y, Faes K, Goossens E. Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation. Hum Reprod Update. 2016;22(6):744–61.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Wallace EM, Groome NP, Riley SC, Parker AC, Wu FC. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: a prospective longitudinal study. J Clin Endocrinol Metab. 1997;82(9):3111–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Gandini L, Lombardo F, Lenzi A, Spano M, Dondero F. Cryopreservation and sperm DNA integrity. Cell Tissue Bank. 2006;7(2):91–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Spermon JR, Ramos L, Wetzels AM, Sweep CG, Braat DD, Kiemeney LA, Witjes JA. Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer. Hum Reprod. 2006;21(7):1781–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Gunnes MW, Lie RT, Bjorge T, Ghaderi S, Ruud E, Syse A, Moster D. Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study. Br J Cancer. 2016;114(3):348–56.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93(2):200–7.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt). 2009;18(3):311–9.CrossRefGoogle Scholar
  57. 57.
    Schrader M, Muller M, Straub B, Miller K. The impact of chemotherapy on male fertility: a survey of the biologic basis and clinical aspects. Reprod Toxicol. 2001;15(6):611–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Green DM, Fiorello A, Zevon MA, Hall B, Seigelstein N. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med. 1997;151(4):379–83.CrossRefPubMedGoogle Scholar
  59. 59.
    Hassold T, Abruzzo M, Adkins K, Griffin D, Merrill M, Millie E, Saker D, Shen J, Zaragoza M. Human aneuploidy: incidence, origin, and etiology. Environ Mol Mutagen. 1996;28(3):167–75.CrossRefPubMedGoogle Scholar
  60. 60.
    Garcia A, Herrero MB, Holzer H, Tulandi T, Chan P. Assisted reproductive outcomes of male cancer survivors. J Cancer Surviv. 2015;9(2):208–14.CrossRefPubMedGoogle Scholar
  61. 61.
    Hsiao W, Stahl PJ, Osterberg EC, Nejat E, Palermo GD, Rosenwaks Z, Schlegel PN. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol. 2011;29(12):1607–11.CrossRefPubMedGoogle Scholar
  62. 62.
    Kopeika J, Khalaf Y, Reddy N. ESHRE poster 2014.
  63. 63.
    Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Faddy M, Gosden R. Numbers of ovarian follicles and testing germ line renewal in the postnatal ovary: facts and fallacies. Cell Cycle. 2007;6(15):1951–2.CrossRefPubMedGoogle Scholar
  65. 65.
    Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62(3):738–44.CrossRefPubMedGoogle Scholar
  67. 67.
    Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence : responses to sex steroid replacement. Br J Obstet Gynaecol. 1999;106:1265–72.CrossRefPubMedGoogle Scholar
  68. 68.
    Salooja N, Szydlo RM, Socie G, Rio B, Chaterjee R, Ljungman P, Late eddects working party of the European group for Blood and Marrow transplantation, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001;358(9278):271–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, Rubin P. Hypothalamic pituitary dysfunction after radiotherapy for brain tumours. N Engl J Med. 1993;328(2):87–94.CrossRefPubMedGoogle Scholar
  70. 70.
    Arbyn M, Simoens C, Goffin F, Noehr B, Bruinsma F. Treatment of cervical cancer precursors: influence of age, completeness of excision and cone depth on therapeutic failure, and on adverse obstetric outcomes. BJOG. 2011;118(10):1274–5. author reply 1275-1276CrossRefPubMedGoogle Scholar
  71. 71.
    Schneider A, Erdemoglu E, Chiantera V, Reed N, Morice P, Rodolakis A, Denschlag D, Kesic V. Clinical recommendation radical trachelectomy for fertility preservation in patients with early stage cervical cancer. Inj J Gynaecol Cancer. 2012;33(4):659–66.CrossRefGoogle Scholar
  72. 72.
    Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG. 2011;118(9):1031–41.CrossRefPubMedGoogle Scholar
  73. 73.
    Cobo A, Garrido N, Pellicer A, Remohi J. Six years’ experience in ovum donation using vitrified oocytes: report of cumulative outcomes, impact of storage time, and development of a predictive model for oocyte survival rate. Fertil Steril. 2015;104(6):1426–34. e1421–1428CrossRefPubMedGoogle Scholar
  74. 74.
    Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probablities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril. 2016;105(2):459–66.CrossRefPubMedGoogle Scholar
  75. 75.
    Argyle CE, Harper JC, Davies MC. Oocyte cryopreservation: where are we now. Hum Reprod Update. 2016;22(4):440–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Druckenmiller S, Goldman KN, Labella PA, Fino ME, Bazzocchi A, Noyes N. Successful oocyte cryopreservation in reproductive aged cancer survivors. Obstet Gynecol. 2016;127(3):474–80.CrossRefPubMedGoogle Scholar
  77. 77.
    Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S. Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes. 2008;15:529–35.CrossRefPubMedGoogle Scholar
  78. 78.
    HFEA – Human Fertilisation and Embryology (1990) European Court of Human Rights judgment is
  79. 79.
    Friedler S, Koc O, Gidoni Y, Raziel A. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis.Fertil. Steril. 2012;97(1):125–33.CrossRefGoogle Scholar
  80. 80.
    Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015;27(3):215–21.CrossRefPubMedGoogle Scholar
  81. 81.
    Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167–70.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, Thurin-Kjellberg A, Nedstrand E, Kitlinski ML, Macklon KT, Ernst E, Fedder J, Tiitinen A, Morin-Papunen L, Einarsson S, Jokimaa V, Hippeläinen M, Lood M, Gudmundsson J, Olofsson JI, Andersen CY. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries- compliation of 20 years of multicenter experience. Acta Obstet Gynecol Scand. 2016;95(9):1015–26.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worlwide in women transplanted with frozen thawed ovarian tissue: focus on birth and perinatal outcomes in 40 of these children. J Assist Reprod Genet. 2016;34(3):325–36.CrossRefPubMedGoogle Scholar
  84. 84.
    Creux H, Monier P, Son WY, Tulandi T, Buckett W. Immature oocyte retrieval and in vitro oocyte maturation at different phases of the menstual cycle in women with cancer who require urgent gonadotoxic treamtent.Fertil. Steril. 2017;107(1):198–204.CrossRefGoogle Scholar
  85. 85.
    Uzelac PS, Delaney AA, Christensen GL, Bohler HC, Nakajima ST. (2015) liver birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryocryopreservation for 5 years. Fertil Steril. 2015 Nov;104(5):1258–60.CrossRefPubMedGoogle Scholar
  86. 86.
    Yin H, Jiang H, Kristensen SG, Andersen CY. Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue. J Assist Reprod Genet. 2016;33(6):741–6.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011;9(11):CD008018.Google Scholar
  88. 88.
    Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76.PubMedGoogle Scholar
  89. 89.
    Shen YW, Zhang XM, Lv M, Chen L, Qin TJ, Wang F, Yang J, Liu PJ, Yang J. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015;8:3349–59.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D’Alonzo A, Canavese G, Pronzato P, Bruzzi P. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40(5):675–83.CrossRefPubMedGoogle Scholar
  91. 91.
    Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(1):65–73.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568–74. Epub 2016 May 23CrossRefPubMedGoogle Scholar
  93. 93.
    Negri G, Herz M, Deola S, Piccin A, Casini M, Babich B, Tauber M, Messini S, Marucci MR, Vittadello F. Abnormal cervical cytology after allogeneic bone marrow transplantation. Am J Clin Pathol. 2014;142(2):222–6.CrossRefPubMedGoogle Scholar
  94. 94.
  95. 95.
    Barbera L, Zwaal C, Elterman D, McPherson K, Wolfman W, Katz A, Matthew A. Interventions to address sexual problems in people with cancer. Curr Oncol. 2017;24(3):192–200.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Quinn MM, Letourneau JM, Rosen MP. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception. 2014;89(5):466–71.CrossRefPubMedGoogle Scholar
  97. 97.
    Soanes L, White ID. Sexual consequences of cancer and its treatment in adolescents and young adults. In cancer in adolescents and young adults. Springer International Publishing 2017, pp. 603–631.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Nivedita Reddy
    • 1
    Email author
  • Caroline L. Furness
    • 2
  • Melanie C. Davies
    • 3
  1. 1.Guy’s and St. Thomas NHS Foundation TrustLondonUK
  2. 2.University Hospitals Bristol NHS Foundation TrustBristolUK
  3. 3.University College London Hospitals (UCLH) NHS Foundation TrustLondonUK

Personalised recommendations